Centre Begins Talks on Trade-Margin Rationalisation for Medical Devices and Hospital Consumables

India’s central government has begun formal discussions with the medical device industry and private hospitals on rationalising trade margins for medical devices, according to ANI, marking the first concrete follow-up step since Maharashtra’s drug regulator flagged extreme markups on hospital consumables earlier this month. Union Minister of Health and Chemicals & Fertilisers J.P. Nadda directed officials to hold the stakeholder discussions after meeting with the Secretary of the Department of Pharmaceuticals, sources told the news agency.

What Prompted the Talks

The discussions follow directly from findings the Maharashtra Food and Drugs Administration flagged earlier this month, which identified markups on items like IV infusion sets, syringes, catheters, and nebulizer masks running as high as 2,841 percent between procurement cost and printed MRP. Those findings prompted the Centre to ask the National Pharmaceutical Pricing Authority to review the pattern, and this week’s stakeholder talks represent the next practical step in that process: rather than simply reviewing the data, the government is now sitting down directly with the industry and hospitals whose pricing practices are under scrutiny.

What Trade-Margin Rationalisation Actually Means

It’s worth being precise about what’s being discussed, since trade-margin rationalisation is a meaningfully different tool than a hard price cap. Rather than fixing an absolute ceiling price for a device, as the NPPA has done for products like cardiac stents and knee implants, trade-margin rationalisation targets the percentage markup allowed between a product’s trade price, what a distributor or hospital pays to acquire it, and its final MRP, the price ultimately charged to a patient. That distinction matters because it applies a consistent rule across a wide range of items regardless of their individual price point, rather than requiring regulators to set and periodically revise a specific ceiling price for every device category one at a time.

The underlying regulatory gap driving this conversation is structural. Under the Drugs (Prices Control) Order, only a small number of medical devices are formally notified as “drugs” and brought under direct price regulation; the vast majority of hospital consumables, everyday items like syringes, gloves, IV sets, and catheters, fall outside that framework entirely, leaving their pricing largely unregulated beyond a general cap on how much MRPs can rise annually.

Industry Voices: A Mixed Reception

Reaction from within the healthcare sector has leaned toward supporting tighter oversight, though not without caveats. Dr. Vivek Srivastava, CEO of Multani Pharmaceuticals, told ANI that the government has already begun addressing scheduled drugs through the Drugs Prices Control Order, but that non-scheduled products, including many medical consumables and devices, still allow companies to set prices largely as they see fit, subject only to MRP approval.

“Patients are often vulnerable and compelled to pay whatever is charged. Such practices must be effectively contained.”

— Dr. Vivek Srivastava, CEO, Multani Pharmaceuticals

He said his own company’s studies found tenfold to twentyfold price variation for identical items compared with their market MRP, and described unnecessary profiteering and excessive markup as unethical, even while acknowledging it is reasonable for hospitals to make a fair profit.

That said, industry concerns about how any rationalisation policy gets implemented are longstanding. When trade-margin rationalisation was previously floated as a policy tool for medical devices, manufacturers and importers raised concerns that a uniform price-capping approach doesn’t work equally well across every device category, and that overly aggressive margin caps risk affecting product quality or availability if manufacturers can’t sustain adequate margins on lower-volume or more specialized devices. That tension, between closing an obvious pricing gap and avoiding unintended consequences for device quality or supply, is likely to shape how the current round of stakeholder discussions unfolds.

Part of a Broader Pricing Push

This week’s talks don’t exist in isolation. Earlier in August, a parliamentary committee on health separately recommended expanding price controls to a broader list of medical devices, including heart valves, pacemakers, and neurosurgical implants, and also called for price caps on private hospital treatments more broadly. Taken together, the parliamentary committee’s recommendations, the Maharashtra FDA’s markup findings, the NPPA review request, and now this week’s stakeholder talks form a fairly coherent sequence of steps, each building on the last, toward a more comprehensive approach to medical device and hospital consumable pricing than India has previously attempted.

A Policy India Has Tried Before

Trade-margin rationalisation itself isn’t a new idea in Indian healthcare policy; the government has floated versions of this approach for medical devices before, and it has historically proven contentious precisely because of the industry pushback described above. That history suggests this week’s talks are unlikely to produce a quick resolution. Rationalising margins across a category as varied as hospital consumables, ranging from a few-rupee syringe to a far more expensive specialized catheter, requires reconciling regulators’ interest in closing an obviously exploitative pricing gap with manufacturers’ and hospitals’ concerns about margin sustainability across genuinely different product categories.

What Comes Next

No timeline has been given for when these stakeholder discussions might produce a formal policy proposal. Given the structural gap in India’s current device-pricing framework and the pattern of escalating attention this issue has received over the past month, from the Maharashtra survey to the NPPA review to now direct ministerial-level talks, the direction of travel appears clear even if the specific mechanism, and how quickly it might take effect, remains to be worked out between the government and the industry stakeholders it’s now negotiating with directly.